SalioGen Therapeutics taps development candidate for ABCA4-mediated Stargardt disease
SGT-1001 uses its novel gene coding technology for gene integration via transposition. It plans to advance SGT-1001 into the clinic in the first half of 2025.
SGT-1001 uses its novel gene coding technology for gene integration via transposition. It plans to advance SGT-1001 into the clinic in the first half of 2025.
Alcon agreed to acquire Belkin Vision and the Belkin Vision Eagle and plans to provide additional details when the deal is closed.
Learn about the four main steps of the Retina Workflow—assessing & educating, planning, treating and checking on how your patients respond to therapy.
With technological advancements in retinal prostheses, patients with severe visual impairment or blindness may have the potential to regain both partial sight and a sense…
Stay in contact with the Global Ophthalmology Summit to get the latest news and updates
The Glaucoma Patient Summit is an annual event that highlights advances in treatment options and provides practical information to help people understand and
The FDA granted de novo marketing authorization to Notal Vision for the patient self-operated AI-powered Scanly Home OCT device, according to a press release.
Organization eyes green practices, shifting ophthalmology landscape.
To evaluate best-corrected visual acuity (BCVA), retina sensitivity (RS), and fixation impairment by microperimetry (MP) due to the presence and severity of disorganization of retinal…
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Ashkan M. Abbey, MD, shares topline data from the phase 2…
➤ Topline results for investigational first-in-class dry eye drop ➤ Dosing complete in second cohort of Stargardt disease gene therapy trial ➤ Enrollment complete for…